Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LY4052031 |
Synonyms | |
Therapy Description |
LY4052031 is an antibody-drug conjugate (ADC) comprising an antibody that targets NECTIN-4 linked to a topoisomerase-1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1872). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY4052031 | LY-4052031|LY 4052031 | LY4052031 is an antibody-drug conjugate (ADC) comprising an antibody that targets NECTIN-4 linked to a topoisomerase-1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1872). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | 0 |